AbbVie Touts Late-Stage Psoriasis Drug Trial Data
AbbVie said its Phase III drug risankizumab is more effective than its own blockbuster drug Humira or J&J's Stelara for psoriasis patients. Source: BioSpace
BlueRock Therapeutics Sets Up HQ in Cambridge, Expands Executive Team
BlueRock Therapeutics established its corporate headquarters in Cambridge, MA and has appointed two additional senior executive staffers. Source: BioSpace
FDA Calls BioMarin's Hemophilia A Drug a Breakthrough
BioMarin announced that the FDA granted its valoctocogene roxaparvovec for Hemophilia A Breakthrough Therapy Designation. Source: BioSpace
Teva Makes Move to Block Eli Lilly From Bringing Its Migraine Drug to the U.S.
Teva said Lilly’s planned drug would infringe five patents that cover its own migraine drug, which it sought U.S. Food and Drug Administration approval for on Oct. 16. Source: BioSpace
FDA to Help Break the Stigma of Drug-Assisted Opioid Addiction Treatments
FDA Commissioner Scott Gottlieb told lawmakers the agency will work to break the stigma associated with medication-assisted treatments for opioid dependence and addiction. Source: Drug Industry Daily
Democratic Lawmakers Introduce Medicare Price Negotiation Bill
Medicare administrators could negotiate lower prices with drug companies, potentially saving the federal government billions of dollars a year, under legislation House and Senate Democrats are introducing in Congress. Source:…
Florida Compounding Pharmacy Broke GMP Rules, FDA Says
A Florida compounding pharmacy did not meet the criteria for exemption from FDA rules on good management practices, and it violated those rules, the FDA said in a warning letter.…
Proposed NJ Rule to Limit Drugmaker Payment to Doctors Could Hurt Drug Development, ACRO Warns
The Association of Clinical Research Organizations warned that the state of New Jersey’s plan to cap drugmaker payments to doctors may hold unintended consequences for drug development efforts. Source: Drug…
The Medicines Company Slashes Hundreds of Jobs in Restructuring
In addition to the layoffs, the company is also looking to divest its Infectious Disease Business. Source: BioSpace
Why Even Spinraza Can't Save Biogen's Incoming MS Meltdown
Biogen released its third-quarter financials yesterday, showing total revenues of $3.1B for the quarter, a 4 percent gain compared to the same period the previous year. Source: BioSpace
- Go to the previous page
- 1
- …
- 278
- 279
- 280
- 281
- 282
- 283
- 284
- …
- 610
- Go to the next page